


Table of Contents For Ex. 1025A

Declaration of Christopher Butler

Affidavit of Christopher Butler ----- page 2

Exhibit A (Webpage Galenic development) ----- page 4



www.archive.org
415.561.6767
415.840-0391 e-fax

Internet Archive
300 Funston Avenue
San Francisco, CA 94118

AFFIDAVIT OF CHRISTOPHER BUTLER

1. I am the Office Manager at the Internet Archive, located in San Francisco, California. I make this declaration of my own personal knowledge.

2. The Internet Archive is a website that provides access to a digital library of Internet sites and other cultural artifacts in digital form. Like a paper library, we provide free access to researchers, historians, scholars, and the general public. The Internet Archive has partnered with and receives support from various institutions, including the Library of Congress.

3. The Internet Archive has created a service known as the Wayback Machine. The Wayback Machine makes it possible to surf more than 400 billion pages stored in the Internet Archive's web archive. Visitors to the Wayback Machine can search archives by URL (i.e., a website address). If archived records for a URL are available, the visitor will be presented with a list of available dates. The visitor may select one of those dates, and then begin surfing on an archived version of the Web. The links on the archived files, when served by the Wayback Machine, point to other archived files (whether HTML pages or images). If a visitor clicks on a link on an archived page, the Wayback Machine will serve the archived file with the closest available date to the page upon which the link appeared and was clicked.

4. The archived data made viewable and browseable by the Wayback Machine is compiled using software programs known as crawlers, which surf the Web and automatically store copies of web files, preserving these files as they exist at the point of time of capture.

5. The Internet Archive assigns a URL on its site to the archived files in the format `http://web.archive.org/web/[Year in yyyy][Month in mm][Day in dd][Time code in hh:mm:ss]/[Archived URL]`. Thus, the Internet Archive URL `http://web.archive.org/web/19970126045828/http://www.archive.org/` would be the URL for the record of the Internet Archive home page HTML file (`http://www.archive.org/`) archived on January 26, 1997 at 4:58 a.m. and 28 seconds (1997/01/26 at 04:58:28). A web browser may be set such that a printout from it will display the URL of a web page in the printout's footer. The date assigned by the Internet Archive applies to the HTML file but not to image files linked therein. Thus images that appear on a page may not have been archived on the same date as the HTML file. Likewise, if a website is designed with "frames," the date assigned by the Internet Archive applies to the frameset as a whole, and not the individual pages within each frame.

6. Attached hereto as Exhibit A are true and accurate copies of printouts of the Internet Archive's records of the HTML files for the URLs and the dates specified in the footer of the printout.

7. I declare under penalty of perjury that the foregoing is true and correct.

DATE: 4/30/15



Christopher Butler

Exhibit A

Galenic development



First-Generation Product

Since August 1994 preparations have been available containing fumaric acid derivatives as the active substance, that have been granted marketing authorisation by the Federal Institute for Drugs and Medical Devices (BfArM) in Germany for treatment of psoriasis. These preparations are administered in the form of enteric film-coated tablets. However there are patients in whom these tablets cause gastrointestinal symptoms, making further treatment problematic or impossible.

Relevant Links

- [Pipeline](#)

Second-Generation Product

For this reason another pharmaceutical form has been developed and at the same time a monosubstance has been used. This new development involves enteric-coated microtablets in capsules intended to guarantee a finer distribution in the gastrointestinal tract, in order to achieve better gastrointestinal tolerance. This has been confirmed by initial results from a pilot study. Other very positive results for the new product from the dose-finding study (Phase II) carried out in 2003 in Poland have already been presented at a conference. Additional studies (Phase III) are either in progress or are in the pipeline and we hope to be able to publish new data soon.

